Biomarker and Treatment Development in Moveme...

In part one of this series, Dr. Greg Cooper talks with Drs. Trey Bateman and Gregg Day about blood-based biomarkers, anti-amyloid therapies, and other highlights from the 2026 Alzheimer Association International Conference. Disclosures can be found at Neurology.org. 

Dr. Shuvro Roy talks with Prof. Catherine Jutzeler about how age influences neurologic and functional recovery after spinal cord injury and how these findings could inform treatment and future clinical trials. Read the related article in Neurology®. Disclosures can be found at Ne ...  Show more

Dr. Jason Crowell talks with Dr. Christopher Gibbons to discuss his paper "Cutaneous Phosphorylated Alpha-Synuclein Deposition in Dementia with Lewy Bodies and Mild Cognitive Impairment."   Show reference:  https://index.mirasmart.com/AAN2024/SearchResults.php?Program_Number=PL4. ...  Show more

Dr. Vikram Karnik and Dr. Rob de Bie discuss early vs. delayed start of Levodopa in early Parkinson disease, and what it means for our clinical practice. Show reference: https://movementdisorders.onlinelibrary.wiley.com/doi/full/10.1002/mds.29796   This podcast is sponsored by arg ...  Show more

Dr. Justin Abbatemarco discusses updates around MOGAD treatments.  Show references: https://jamanetwork.com/journals/jamaneurology/article-abstract/2822964   https://jnnp.bmj.com/content/95/11/1054   

Biomarkers are one of the most exciting and fast-evolving areas in multiple sclerosis research, offering promise for earlier diagnosis, accurate prognosis, and truly personalised treatment. Yet despite their potential, there is still significant debate that limits their widesprea ...  Show more